CMND Announces $10M Financing Agreement to Explore Strategic Opportunities

Rhea-AI Filing Summary

Clearmind Medicine announced a $10.0 million securities purchase agreement intended to explore strategic opportunities. The filing provides the transaction title but no additional terms, counterparties, or timing. The report is signed by CEO Adi Zuloff-Shani, confirming the company disclosed the financing arrangement publicly. With limited detail in this report, the primary fact is the existence of the $10 million agreement to support potential strategic initiatives.

Positive

• Clearmind secured a $10.0 million securities purchase agreement, indicating available capital to pursue strategic opportunities
• Disclosure signed by CEO Adi Zuloff-Shani, confirming company authorization and formal reporting

Negative

• Key terms are not disclosed—the filing omits pricing, security type, counterparties, use of proceeds, and closing conditions
• Insufficient detail to assess dilution or valuation impact for investors from this report alone

Insights

Securities Analyst

TL;DR: Company disclosed a $10M securities purchase agreement; material but lacking terms makes investor impact unclear.

Clearmind's announcement of a $10.0 million securities purchase agreement signals access to capital that could fund strategic initiatives or liquidity needs. Because the filing contains no information on pricing, dilution, counterparty identity, use of proceeds, or closing conditions, assessing valuation impact, dilution, or covenant risk is impossible from this document alone. From a capital markets perspective, the existence of a committed financing is a positive liquidity indicator, but the absence of terms prevents determining whether the agreement is accretive or dilutive to existing shareholders.

Corporate Finance Specialist

TL;DR: $10M commitment could materially affect operations or strategy, but missing specifics limit actionable conclusions.

The disclosed securities purchase agreement of $10 million is a notable corporate finance event because it represents potential new funding. However, crucial details—security type, conversion features, pricing, expiration, and counterparty—are not provided in this filing. Those details drive capitalization effects, potential governance changes, and strategic flexibility. Without them, one can only record the funding intent; impact on balance sheet structure and shareholder value remains indeterminate from this notice alone.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: September 2025

Commission file number: 001-41557

CLEARMIND MEDICINE INC.

(Translation of registrant’s name into English)

101 – 1220 West 6th Avenue

Vancouver, British Columbia

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒    Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on September 19, 2025, titled “Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities”.

1

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Clearmind Medicine Secures $10 million Securities Purchase Agreement to Explore Strategic Opportunities”

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Clearmind Medicine, Inc.
	(Registrant)
Date: September 19, 2025	By:	/s/ Adi Zuloff-Shani
	Name:	Adi Zuloff-Shani
	Title:	Chief Executive Officer

3

FAQ

What did Clearmind Medicine (CMND) announce in this 6-K?

The company disclosed a $10.0 million securities purchase agreement intended to explore strategic opportunities; no further terms are provided.

Does the filing state the type of securities sold under the agreement?

No. The filing title notes a securities purchase agreement but does not specify the security type or other terms.

Who signed the disclosure for Clearmind Medicine?

The report is signed by Adi Zuloff-Shani, Chief Executive Officer.

Can investors determine dilution or pricing from this filing?

No. The filing does not include pricing, share counts, or conversion features, so dilution and pricing effects cannot be determined.

Is the $10 million immediately available to Clearmind?

The filing does not state whether the funds have been received or the closing conditions; it only discloses the existence of the agreement.